Acumen Pharmaceuticals
ABOS
69 hedge funds and large institutions have $61.1M invested in Acumen Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 27 reducing their positions, and 15 closing their positions.
1,500% more call options, than puts
Call options by funds: $48K | Put options by funds: $3K
40% more capital invested
Capital invested by funds: $43.6M → $61.1M (+$17.5M)
3% less funds holding
Funds holding: 71 → 69 (-2)
3.11% less ownership
Funds ownership: 62.1% → 58.99% (-3.1%)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
67% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$684K |
| 2 |
SG Americas Securities
New York
|
+$559K |
| 3 |
Renaissance Technologies
New York
|
+$467K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$108K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.87M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.07M |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$291K |
| 4 |
Pathstone Holdings
Englewood,
New Jersey
|
-$276K |
| 5 |
Goldman Sachs
New York
|
-$260K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
76
Schonfeld Strategic Advisors
New York
| – | -$18.5K | -15,929 | Closed |
|
|
EI
77
Ethic Inc
New York
| – | -$12.7K | -11,377 | Closed |
|
|
DS
78
DRW Securities
Chicago,
Illinois
| – | -$12.8K | -11,018 | Closed |
|
|
TRCT
79
Tower Research Capital (TRC)
New York
| – | -$4.21K | -3,631 | Closed |
|
|
FDCDDQ
80
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$1.74K | -1,500 | Closed |
|
|
BIG
81
Brooklyn Investment Group
Brooklyn,
New York
| – | -$719 | -619 | Closed |
|
82
Raymond James Financial
St Petersburg,
Florida
| – | -$574 | -495 | Closed |
|
|
CA
83
Clearstead Advisors
Cleveland,
Ohio
| – | -$74 | -63 | Closed |
|
|
TWD
84
True Wealth Design
Akron,
Ohio
| – | -$41 | -35 | Closed |
|
ABOS Hedge Fund Activity: Q3 2025 in Review
69 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q3 2025, worth a combined $61.1M — up 40% from $43.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ABOS and 13 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 9 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $684K. The largest seller was Millennium Management, cutting an estimated $1.87M.
- 69 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q3 2025, down from 71 in Q2 2025.
- Funds reported $61.1M of Acumen Pharmaceuticals stock for Q3 2025, up 40% quarter-over-quarter.
- 13 funds opened new Acumen Pharmaceuticals positions in Q3 2025 and 15 closed out, a net change of -2 holders.
- The largest Acumen Pharmaceuticals buyer in Q3 2025 was Citadel Advisors, an estimated $684K added.
- The largest Acumen Pharmaceuticals seller in Q3 2025 was Millennium Management, an estimated $1.87M sold.
Based on aggregated 13F filings for Q3 2025.